Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity.
Hong TH, Cha H, Shim JH, Lee B, Chung J, Lee C, Kim NKD, Choi YL, Hwang S, Lee Y, Park S, Jung HA, Kim JY, Park YH, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH, Park WY.
Hong TH, et al.
J Immunother Cancer. 2020 Oct;8(2):e001199. doi: 10.1136/jitc-2020-001199.
J Immunother Cancer. 2020.
PMID: 33077514
Free PMC article.